Cherwell Sets New Vision for Future of ITSM at 5th Annual Global Conference
Oct 16, 2017 12:05 pm UTC| Business
COLORADO SPRINGS, Colo., Oct. 16, 2017 -- More than 700 customers and partners will come together this week at Cherwell Software’s fifth annual Global Conference (CGC), to discuss IT’s evolving role and how the ITSM...
UniFirst Racing Returns for Back-to-Back NASCAR Races in October
Oct 16, 2017 12:05 pm UTC| Business
WILMINGTON, Mass., Oct. 16, 2017 -- The No. 5 UniFirst Chevrolet SS returns to the NASCAR track for two races in October. UniFirst Corporation (NYSE:UNF), a leading provider of customized work uniform programs,...
Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum
Oct 16, 2017 12:03 pm UTC| Business
CORAL GABLES, Fla., Oct. 16, 2017 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating...
Oct 16, 2017 12:02 pm UTC| Business
Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis - Late-breaking oral abstract presented at the World Congress of...
Genedrive PLC: genedrive signs distribution agreement with Sysmex Europe GmbH("Sysmex Europe")
Oct 16, 2017 12:02 pm UTC| Business
For release: 16 October 2017 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the...
ASML reports transactions under its current share buyback program
Oct 16, 2017 12:02 pm UTC| Business
VELDHOVEN, the Netherlands - ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. Date Total repurchased shares Weighted average price Total repurchased...
Oct 16, 2017 12:01 pm UTC| Business
Five of eight progressive MS patients who received the full course of autologous ATA190 experienced clinical improvements Further results for all 10 patients in the ongoing Phase 1 study will be presented at the MSParis...